Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Matsumoto, Masanori ^a   Bennett, Charles L ^b   Isonishi, Ayami ^a   Qureshi, Zaina ^b   Hori, Yuji ^a   Hayakawa, Masaki ^a   Yoshida, Yoko ^a   Yagi, Hideo ^a   Fujimura, Yoshihiro ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF SOUTH CAROLINA COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ENZYME INHIBITOR; HEMOGLOBIN; NITROGEN; UNCLASSIFIED DRUG; UREA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE INHIBITOR; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ACQUIRED IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA; ADAMTS13 DEFICIENCY; ADULT; AGE DISTRIBUTION; ARTICLE; ASIA; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; EUROPE; FEMALE; FEVER; HEMATOCRIT; HOSPITALIZATION; HUMAN; JAPAN; KIDNEY DISEASE; KOREA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; ONSET AGE; SEX RATIO; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES; UREA NITROGEN BLOOD LEVEL; AGE; BLOOD; IDIOPATHIC THROMBOCYTOPENIC PURPURA; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY;

ADAM PROTEINS; AGE FACTORS; COHORT STUDIES; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; STATISTICS, NONPARAMETRIC;

EID: 84858022582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033029     Document Type: Article

References (21)

1. Amorosi EL, Ultmann JE, (1966) Thrombotic thrombocytopenic purpura:report of 16 cases and review of the literature. Medicine 45: 139-159.
2. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, et al. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339: 1578-1584.
3. Tsai HM, Lian EC, (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339: 1585-1594.
4. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488-494.
5. Scheiflinger F, Knobl P, Trattner B, Trattner B, Plaimauer B, et al. (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102: 3241-3243.
6. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, et al. (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109: 2815-2822.
7. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, et al. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102: 60-68.
8. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE, (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103: 4043-4049.
9. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, et al. (2004) Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 83: 233-244.
10. Kremer-Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN, (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115: 1500-1511.
11. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP, (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98: 1765-1772.
12. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, et al. (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142: 819-826.
13. Jang MJ, Chong SY, Kim IH, Kim JH, Jung CW, et al. (2011) Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. Int J Hematol 93: 163-169.
14. Wyllie BF, Garg AX, Macnab J, Rock GA, Clark WF, et al. (2006) Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol 132: 204-209.
15. Tsai HM, (2000) High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol 65: 251-255.
16. Bohm M, Betz C, Miesbach W, Krause M, von Auer C, et al. (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 129: 644-652.
17. Fujimura Y, Matsumoto M, (2009) Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 49: 7-15.
18. Furlan M, Robles R, Lämmle B, (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87: 4223-4234.
19. Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, et al. (2001) Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 74: 101-108.
20. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, et al. (2006) Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 46: 1444-1452.
21. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, et al. (1975) Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 612.